Moclobemide NEW
| Price | $43 | $68 | $103 |
| Package | 25mg | 50mg | 100mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: Moclobemide | CAS No.: 71320-77-9 |
| Purity: 99.51% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | Moclobemide |
| Description | Moclobemide (Ro111163) is a reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties. |
| In vitro | Moclobemide orally administered 2 hours before decapitation preferentially inhibits MAO-A and PEA in rat brain with ED50 of 7.6 μmol/kg and 78 μmol/kg, respectively. Moclobemide orally administered 2 hours before decapitation preferentially inhibits MAO-A and PEA in rat liver with ED50 of 8.4 μmol/kg and 6.6 μmol/kg, respectively. Moclobemide (0.1 mM), which inhibits brain MAO-A activity by over 80%, does not affect benzylamine oxidase (rat heart) and diamine oxidase (rat small intestine) activity in vitro. [1] Moclobemide (10 mM-100 mM) includes in the culture medium during anoxia or with glutamate significantly increases in a concentration-dependent manner the amount of surviving neurons compared to controls in neuronal-astroglial cultures from rat cerebral cortex. [2] |
| In vivo | Moclobemide (10 mg/kg p.o.) induces a significant decrease of all monoamine metabolites measured in rat brain. [1] Moclobemide, given via the drinking water (4.5 mg/kg/day), produces significant decreases in adrenal weight of rats after 5 (-23%) and 7 weeks (-16%) of treatment. Moclobemide upregulates hippocampal mineralocorticoid receptor (MR) levels in rats by 65%, 76% and 19% at 2 weeks, 5 weeks and 7 weeks of treatment, and upregulates Glucocorticoid receptor (GR) levels in this limbic brain structure by 10% at 5 weeks. Moclobemide treatment (5 weeks, 4.5 mg/kg/day) significantly attenuates stress (30 min novel environment)-induced plasma ACTH (-35%) and corticosterone (-29%) levels. [3] Moclobemide (2.5 mg/kg/day) decreases immobility and increases climbing behavior following treatment for 3 days, but increases in both swimming and climbing behaviors are measured following treatment for 14 days. Moclobemide (15 mg/kg/day) decreased immobility and increased swimming for 3 days, whereas treatment for 14 days significantly increases both active behavior (swimming and climbing). [4] Moclobemide (100 mg/kg/day) combined with triethyltin blocks the development of brain edema and the increase in the cerebral chloride content induced by triethyltin in rats. Moclobemide (100 mg/kg/day) reduces the increase in the cerebral sodium content and attenuates the neurological deficit in rats. [5] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 26.9 mg/mL (100.1 mM), Sonication is recommended. DMSO : 125 mg/mL (465.13 mM), Sonication is recommended. 10% DMSO+90% Saline : 10 mg/mL (37.21 mM), Solution. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (7.44 mM), Sonication is recommended. |
| Keywords | stress | Ro-111163 | Ro 111163 | progenitor | oxidase,MAO-A | neurotrophic | neurogenesis | MonoamineOxidase | Monoamine Oxidase | monoamine | Moclobemide | MAO-A (5-HT) | MAO | Inhibitor | inhibit | hippocampal | brain-derived | antidepressants |
| Inhibitors Related | Safinamide | 1,4-Naphthoquinone | 4-Chlorochalcone | Paeonol | Hydroxylamine hydrochloride | Isatin | Methylene Blue trihydrate | β-Aminopropionitrile | Aminoacetone hydrochloride | Allylthiourea | D-(-)-Quinic acid | Amitraz |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Mitochondrial Membrane Protein-Targeted Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Antidepressant Compound Library | EMA Approved Drug Library | Drug Repurposing Compound Library | CNS-Penetrant Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-08 | ||
|
VIP7Y
|
Jinan Jianfeng Chemical Co., Ltd
|
2026-06-08 | ||
|
VIP2Y
|
Xi an Biohorlden Industry Trade Co Ltd
|
2026-06-04 | ||
| $68.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
| $68.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
|
VIP5Y
|
Zhejiang J&C Biological Technology Co.,Limited
|
2025-12-25 | ||
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-12-01 | ||
|
VIP4Y
|
Dingwang Technology (Wuhan) Co., Ltd.
|
2025-08-22 | ||
| $90.00 |
Guangzhou Tengyue Chemical Co., Ltd.
|
2025-04-21 | ||
| $200.00 |
Wuhan Qiami Technology Co., Ltd
|
2022-07-12 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY